Table 1.
Baseline characteristics of patients treated.
Table 2.
Extracorporal treatment and concomitant immunosuppression.
Figure 1.
Anti-GBM antibody levels from start of immunoadsorption until end of observation.
Mean values ± standard deviation of all patients measured with ELISA depicted. Grey area denotes negativity of the assay.
Table 3.
Renal function and patient survival.
Figure 2.
Anti-GBM antibody kinetics and renal function in patient #7 (2a) and patient #10 (2b).
Antibody values at diagnosis, before and after IAS, 12 hours in between sessions and up to 6 weeks; arrows depict daily IAS sessions. Grey area depicts negativity of the assay.
Figure 3.
Dynamics of serum-creatinine of individual patients.
Observation period from start of IAS until 5 years. White coloured time points depict positive anti-GBM antibody testing.
Figure 4.
Cumulative costs of immunoadsorption and plasma exchange.
Circles and triangles depict earliest timepoints of adsorber change due to reduced adsorption capacity (every 25 treatments for Immunosorba, every 35 treatments for Globaffin).